Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment

Purpose: Hypertension (HTN) is considered a major health problem. Apelin (AP) a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control, Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous...

Full description

Bibliographic Details
Main Author: Faisal Gh. Al-Rubaye
Format: Article
Language:English
Published: Cukurova University 2013-02-01
Series:Çukurova Üniversitesi Tıp Fakültesi Dergisi
Subjects:
Online Access:http://www.scopemed.org/fulltextpdf.php?mno=22963
id doaj-c0d72647c4144ea6b8e1e0ae23206ad4
record_format Article
spelling doaj-c0d72647c4144ea6b8e1e0ae23206ad42020-11-24T21:08:15ZengCukurova UniversityÇukurova Üniversitesi Tıp Fakültesi Dergisi0250-51502013-02-0138116Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatmentFaisal Gh. Al-RubayePurpose: Hypertension (HTN) is considered a major health problem. Apelin (AP) a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control, Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them and the effect of antihypertensive drugs from various classes on these parameters of endothelial function. The aim of this study is to assess the status of Apelin and Assymetric DiMethyl Arginine in essential Hypertension on various modalities of treatment. Methods: The present study is a cross-sectional study (2007/2008) at Al-Yarmouk Teaching Hospital. Includes measurement of serum AP and ADMA in patients with hypertension. a total of 80 patients with HTN were involved in this study, they were classified according to modality of treatment as Hypertensives on captopril G1: (n=40); Hypertensives on atenolol G2: (n=40). A matching group of eighty apparently healthy volunteers who were included as controls (n=80. Results: Serum AP was significantly reduced and serum ADMA was significantly elevated in hypertensive patients (G1 & G2) as compared with controls (G3) (p < 0.001), also the above significant alteration in these two parameters was found when hypertensives on atenolol (G2) were compared with hypertensives on captopril (G1) (p < 0.001). AP was negatively correlated with ADMA (r = -0.9, p<0.05 for G1) (r = -0.8, p<0.05 for G2); however, this correlation was lost in control group. Conclusion: Patients with HTN have high level of serum ADMA associated with low level of AP compared with controls, both AP and ADMA were negatively correlated; this was most pronounced in G2 indicating positive effects of captopril on NO pathway. [Cukurova Med J 2013; 38(1.000): 1-6]http://www.scopemed.org/fulltextpdf.php?mno=22963hypertensionApelinasymmetric dimethyl argininecaptoprilatenelol
collection DOAJ
language English
format Article
sources DOAJ
author Faisal Gh. Al-Rubaye
spellingShingle Faisal Gh. Al-Rubaye
Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
Çukurova Üniversitesi Tıp Fakültesi Dergisi
hypertension
Apelin
asymmetric dimethyl arginine
captopril
atenelol
author_facet Faisal Gh. Al-Rubaye
author_sort Faisal Gh. Al-Rubaye
title Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
title_short Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
title_full Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
title_fullStr Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
title_full_unstemmed Serum concentration of Apelin and Asymmetric Dimethylarginine in hypertensive patients on different modalities of treatment
title_sort serum concentration of apelin and asymmetric dimethylarginine in hypertensive patients on different modalities of treatment
publisher Cukurova University
series Çukurova Üniversitesi Tıp Fakültesi Dergisi
issn 0250-5150
publishDate 2013-02-01
description Purpose: Hypertension (HTN) is considered a major health problem. Apelin (AP) a novel multifunction peptide implicated in regulation of the cardiovascular system, including blood pressure and cardiac function control, Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions. However, there is no data about ADMA and apelin levels in essential hypertension and any relationship between them and the effect of antihypertensive drugs from various classes on these parameters of endothelial function. The aim of this study is to assess the status of Apelin and Assymetric DiMethyl Arginine in essential Hypertension on various modalities of treatment. Methods: The present study is a cross-sectional study (2007/2008) at Al-Yarmouk Teaching Hospital. Includes measurement of serum AP and ADMA in patients with hypertension. a total of 80 patients with HTN were involved in this study, they were classified according to modality of treatment as Hypertensives on captopril G1: (n=40); Hypertensives on atenolol G2: (n=40). A matching group of eighty apparently healthy volunteers who were included as controls (n=80. Results: Serum AP was significantly reduced and serum ADMA was significantly elevated in hypertensive patients (G1 & G2) as compared with controls (G3) (p < 0.001), also the above significant alteration in these two parameters was found when hypertensives on atenolol (G2) were compared with hypertensives on captopril (G1) (p < 0.001). AP was negatively correlated with ADMA (r = -0.9, p<0.05 for G1) (r = -0.8, p<0.05 for G2); however, this correlation was lost in control group. Conclusion: Patients with HTN have high level of serum ADMA associated with low level of AP compared with controls, both AP and ADMA were negatively correlated; this was most pronounced in G2 indicating positive effects of captopril on NO pathway. [Cukurova Med J 2013; 38(1.000): 1-6]
topic hypertension
Apelin
asymmetric dimethyl arginine
captopril
atenelol
url http://www.scopemed.org/fulltextpdf.php?mno=22963
work_keys_str_mv AT faisalghalrubaye serumconcentrationofapelinandasymmetricdimethylarginineinhypertensivepatientsondifferentmodalitiesoftreatment
_version_ 1716760264670445568